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The NLRP3 inflammasome, a molecular platform that modulates innate immune functions by activation of caspase-1, catalyzes the proteolytic processing and secretion of IL-1β and IL-18 in immune cells 1, 2 . Cellular metabolites have been linked to NLRP3 inflammasome activation [3] [4] [5] . We have previously reported that cellular metabolic pathways, including glycolysis and fatty acid synthesis, are associated with NLRP3 inflammasome activation in macrophages under pro-inflammatory conditions 6, 7 . Notably, fatty acid metabolism has been linked to NLRP3 inflammasome activation 4, 5, 7 , a process that is implicated in metabolic diseases such as obesity-derived diabetes or insulin resistance 8 . As a mechanism for the utilization of fatty acids, FAO is a major bioenergetic pathway that is upregulated under conditions of prolonged fasting, exercise or metabolic stress 9, 10 . Among the enzymes in the FAO pathway, the reduced activity of CPT1A, which is essential for the proper transport and oxidation of long-chain fatty acids (LCFAs) in mitochondria, may promote type 2 diabetes and insulin resistance 11, 12 . Recently, mitochondrial NOX4 has been implicated in oxidative stress and mitochondrial function in the kidney and heart of individuals with diabetes [13] [14] [15] [16] [17] [18] [19] [20] [21] . Currently, the role of NOX4 in regulating cellular metabolism during NLRP3 inflammasome activation remains incompletely understood. Here we sought to identify the mechanisms by which NOX4 regulates the NLRP3 inflammasome, which is a key mediator of macrophagedependent inflammation through regulation of mitochondriadependent metabolic pathways.
RESULTS

Deficiency of NOX4 suppresses NLRP3 inflammasome activation
To investigate the function of NOX4 in NLRP3 inflammasome activation, we analyzed whether genetic deficiency of Nox4 could suppress the secretion of IL-1β and IL-18 in lipopolysaccharide (LPS)-primed bone marrow (BM)-derived macrophages (BMDMs) in response to specific NLRP3 inflammasome activators, including nigericin, ATP and silica. BMDMs from Nox4 −/− mice showed significantly lower IL-1β and IL-18 secretion (Fig. 1a) in response to nigericin, ATP and silica, as compared to BMDMs from wild-type (WT) mice, whereas secretion of tumor necrosis factor (TNF)-α, which is an indicator of toll-like receptor 4 (TLR4) signaling, was unchanged (Fig. 1a) . In contrast, a deficiency of NOX4 had no effect on the secretion of IL-1β and IL-18 in response to muramyldipeptide (MDP), a NLRP1 inflammasome activator, or flagellin, a NLRC4 inflammasome activator (Fig. 1a) . IL-1β secretion was not changed , as determined by ELISA, (e) from primary human macrophages that were transduced with lentivirus expressing either of two independent NOX4-targeting gRNAs (NOX4 gRNA #1 and NOX4 gRNA #2), or with a control plasmid (control), and that were stimulated with LPS and either nigericin or ATP (n = 3 human subjects). White bars that are not visible have very low (near-zero) values. (f,g) Amounts of IL-1β (left), IL-18 (middle) and TNF-α (right), as determined by ELISA, (f) and representative immunoblot analysis (g) for NOX4 and caspase-1 in lung tissues (100 µg) from WT and Nox4 −/− mice after infection of S. pneumoniae (n = 10 mice per group) or PBS (n = 3 mice per group) for 24 h. (h) Survival curve of WT and Nox4 −/− mice after S. pneumoniae infection (n = 30 mice per group). P = 0.0121 by log-rank test. For immunoblots, TOMM20 and β-actin were used as loading controls. All data are mean ± s.d. Unless otherwise indicated, **P < 0.01, *P < 0.05; by analysis of variance (ANOVA). Data are representative of three independent experiments, and each was done in triplicate. response to LPS and nigericin treatment were lower relative to that in cells transduced with the control plasmid (Fig. 1d) . Consistently, the secretion of IL-1β and IL-18 in response to nigericin and ATP were significantly lower in cells transduced with the two NOX4-targeted gRNAs than in cells transduced with the control plasmid (Fig. 1e) ; the secretion of TNF-α was unchanged (Supplementary Fig. 1b) . Next we investigated the role of NOX4 in a mouse model of S. pneumoniae lung infection. S. pneumoniae, a leading cause of pneumonia and meningitis, activates the NLRP3 inflammasome through its secreted pore-forming toxin pneumolysin 22, 23 . The levels of IL-1β, IL-18 and TNF-α (Fig. 1f) , the expression of NOX4 protein and the activation of caspase-1 (Fig. 1g) in lung tissues of WT mice were higher after S. pneumoniae infection relative to that in vehicle-treated mice. Notably, the levels of IL-1β and IL-18 ( Fig. 1f) and of caspase-1 activation (Fig. 1g) in lung tissues were significantly lower in S. pneumoniaeinfected Nox4 −/− mice than in infected WT mice, whereas TNF-α levels were comparable (Fig. 1f) . Moreover, Nox4 −/− mice were more resistant to S. pneumoniae-induced mortality 150 h after infection than WT mice (Fig. 1h) . Furthermore, the plasma levels of IL-1β and IL-18 in response to LPS challenge in vivo was significantly lower in Nox4 −/− mice than in WT mice, whereas levels of TNF-α were unchanged ( Supplementary Fig. 1c ). These results suggest that NOX4 regulates NLRP3 inflammasome activation in vitro and in vivo.
NOX4 regulates FAO during NLRP3 inflammasome activation
We next investigated the underlying molecular mechanism by which NOX4 regulates NLRP3 inflammasome activation. Of the six genes that we tested encoding isoforms of NOX (Nox1 to Nox4 and dual oxidase 1 (Duox1) and Duox2), we identified that Nox4 gene expression was higher in response to ATP treatment in LPS-primed WT BMDMs, relative to that in BMDMs treated with LPS or ATP alone or in untreated BMDMs, whereas the expression of the other NOX-encoding genes were not specifically regulated by LPS and ATP stimulation (Supplementary Fig. 1d ). Furthermore, we found that NOX4 protein was preferentially expressed in mitochondria and that its expression was markedly higher in response to nigericin and ATP stimulation in LPS-primed WT BMDMs, relative to that in BMDMs treated with LPS alone or to untreated cells (Fig. 2a) . Moreover, NOX4 protein expression was increased in response to treatment with nigericin and ATP in a time-and dose-dependent manner in LPS-primed WT BMDMs ( Supplementary Fig. 1e,f) , whereas treatment with LPS alone did not induce NOX4 expression (Supplementary Fig. 1g ). Consistently, treatment with silica and monosodium urate (MSU), as well as with Aeromonas hydrophila aerolysin, which are representative of particulate and bacterial toxin inducers of NLRP3, respectively, resulted in higher NOX4 protein expression and IL-1β secretion in LPS-primed WT BMDMs ( Supplementary Fig. 1h,i) .
Next we examined whether NOX4-derived reactive oxygen species (ROS) could regulate cellular metabolism during NLRP3 inflammasome activation. Nox4 −/− BMDMs had significantly lower mitochondrial ROS (mtROS) production in response to treatment with LPS and nigericin than WT BMDMs (Fig. 2b) . Because ROS is associated with FAO in myoblasts 24 , we analyzed the regulation of FAO by NOX4 during NLRP3 inflammasome activation. We observed that the uptake of free fatty acids (FFAs), including LCFAs and poly-unsaturated fatty acids (PUFAs), were significantly higher in response to treatment with LPS and ATP in WT BMDMs, relative to that for LPS alone, or to untreated cells (Supplementary Fig. 2a) . FFAs levels were significantly lower in Nox4 −/− BMDMs than in WT BMDMs, in response to LPS and nigericin stimulation (Fig. 2c) . Consistently, in response to LPS and nigericin, the protein expression of LCFA transporter cluster of differentiation 36 (CD36), which facilitates the cellular uptake of LCFAs such as palmitate and stearate 25 , was lower in Nox4 −/− BMDMs than in WT BMDMs (Supplementary Fig. 2b) .
Because FFAs are broken down and used by FAO for release of energy 9 , we evaluated whether NOX4 could regulate FAO during NLRP3 inflammasome activation. We measured the oxidation of fatty acids by monitoring cellular oxygen-consumption rate (OCR) with palmitate-BSA as an FAO substrate 9, 26 . The OCR was higher in response to nigericin stimulation in LPS-primed WT BMDMs than in WT BMDMs treated with LPS alone or in untreated control cells, and this relative response to LPS and nigericin was higher in response to palmitate-BSA treatment ( Fig. 2d and Supplementary  Fig. 2c ). Nox4 −/− BMDMs had lower OCR than WT BMDMs in response to palmitate-BSA after LPS and nigericin treatments ( Fig. 2d and Supplementary Fig. 2c) . In contrast to Nox4 −/− BMDMs, the activation of FAO by palmitate-BSA in LPS-primed WT BMDMs resulted in higher caspase-1 activation, IL-1β cleavage ( Fig. 2e and Supplementary Fig. 2d ), and secretion of IL-1β and IL-18 ( Fig. 2f ) in response to nigericin and ATP, relative to that in LPS-primed WT BMDMs treated with BSA, whereas TNF-α was unchanged in both WT and Nox4 −/− BMDMs (Fig. 2f) . Similar to treatment with palmitate-BSA, treatment with BSA-conjugated stearic acid, one of the most common saturated fatty acids 27 , resulted in higher caspase-1 activation, IL-1β cleavage ( Supplementary Fig. 2e,f) , and secretion of IL-1β and IL-18 ( Supplementary Fig. 2g ) in response to nigericin and ATP relative to that in vehicle-treated cells, whereas TNF-α levels were unchanged (Supplementary Fig. 2g ). Nox4 −/− BMDMs had lower caspase-1 activation, IL-1β cleavage ( Supplementary  Fig. 2e,f) , and secretion of IL-1β and IL-18 ( Supplementary Fig. 2g ) in response to stearic acid-BSA than WT BMDMs.
Because the oxidation of FAs by FAO generates acetyl-coenzyme A (acetyl-CoA), which fuels the tricarboxylic acid cycle (TCA) cycle 8, 9 , the levels of acetyl-CoA were higher in response to either nigericin or palmitate-BSA and nigericin in WT BMDMs, relative to those in Nox4 −/− BMDMs (Fig. 2g) . Because the extracellular acidification rate (ECAR), an index of the glycolytic rate, was comparable between WT and Nox4 −/− BMDMs, lower acetyl-CoA production in Nox4 −/− BMDMs was not affected by glycolysis (Supplementary Fig. 2h ). In contrast, the protein expression of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway 28 , was comparable between WT and Nox4 −/− BMDMs in response to LPS and nigericin stimulation (Supplementary Fig. 2i ).
Next we investigated whether NOX4-dependent FAO could regulate the oligomerization of the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which is required for NLRP3-dependent caspase-1 activation 29, 30 . The formation of ASC monomers and higher complexes ( Fig. 2h ) and of specks ( Fig. 2h) that were induced by LPS and nigericin stimulation was greater in WT BMDMs than in Nox4 −/− BMDMs. Furthermore, NOX4 overexpression resulted in higher levels of FFA and acetyl-CoA in response to nigericin in LPS-primed WT peritoneal macrophages, as compared to that in control cells (Fig. 2i) . Moreover, NOX4 overexpression resulted in higher caspase-1 activation, IL-1β cleavage (Fig. 2j) , and secretion of IL-1β and IL-18 ( Fig. 2j ) in response to LPS and nigericin relative to that in control cells, whereas TNF-α secretion was unchanged (Fig. 2j) . In the absence of LPS priming, NLRP3 overexpression supported caspase-1 activation in response to nigericin or ATP (Supplementary Fig. 3a) , and this effect was Fig. 3b ). These results suggest that NOX4 regulates FAO during NLRP3 inflammasome activation.
NOX4 regulates CPT1A during NLRP3 inflammasome activation
We next investigated the targets of NOX4 in the regulation of FAO during NLRP3 inflammasome activation. Notably, Nox4 −/− BMDMs showed lower expression of CPT1A, which is a key enzyme for mitochondrial FAO 31 , in response to LPS and nigericin, relative to that in WT BMDMs (Fig. 3a) , whereas the expression of CPT1C and acyl-coenzyme A oxidase 1 (ACOX1), which is a key enzyme of peroxisomal FAO 32 , was comparable (Fig. 3a) . Because K + efflux is increased by specific NLRP3 inflammasome activators 33 , we investigated whether K + efflux could regulate NOX4 and CPT1A expression during NLRP3 inflammasome activation. We first analyzed the regulation of NOX4 by K + efflux. The expression of Nox4 in response to nigericin was significantly lower in the presence of high levels of extracellular K + in LPS-primed WT BMDMs than in vehicle-treated cells (Fig. 3b) . Consistently, the induction of NOX4 and CPT1A protein expression, the activation of caspase-1, the cleavage of IL-1β and the secretion of IL-1β ( Fig. 3c and Supplementary  Fig. 3c ) in response to nigericin were lower in the presence of high extracellular K + concentrations in LPS-primed WT BMDMs relative to those in control cells, whereas TNF-α secretion was unchanged (Supplementary Fig. 3c) . Similarly, treatment with glyburide, an inhibitor of ATP-sensitive K + (K ATP ) channels 34 , resulted in reduced NOX4 and CPT1A expression, caspase-1 activation, IL-1β cleavage (Supplementary Fig. 3d ) and secretion of IL-1β ( Supplementary  Fig. 3e ) in response to nigericin relative to control, whereas TNF-α secretion was unchanged (Supplementary Fig. 3e ). In contrast, the higher expression of NOX4 and CPT1A in response to LPS and nigericin was not altered in Nlrp3 −/− BMDMs as compared to that in WT BMDMs (Supplementary Fig. 3f ).
To investigate the molecular mechanism by which NOX4 regulates the expression of CPT1A, we analyzed the role of NOX4-derived mtROS in regulating CPT1A expression during NLRP3 inflammasome activation. Treatment with Mito-TEMPO, a specific scavenger of mitochondrial superoxide 35 , resulted in lower protein expression of CPT1A, caspase-1 activation and IL-1β cleavage in response to nigericin in LPS-primed WT BMDMs compared to control (Fig. 3d) . Consistently, as compared to control treatments, Mito-TEMPO treatment resulted in significantly lower induction of OCR by palmitate-BSA ( Fig. 3e and Supplementary Fig. 3g ) and levels of FFA (Fig. 3f) in response to nigericin. In contrast, the protein expression of peroxisome proliferator activated receptor, gamma, coactivator 1 alpha (PPARGC1A; also known as PGC-1α), which is a key transcription factor that regulates the expression of proteins involved in fatty acid uptake and oxidation 36 , was comparable between Nox4 −/− and WT BMDMs (Supplementary Fig. 3h) . Consistently, the expression of Cpt1a was not changed in response to LPS and nigericin in Nox4 −/− BMDMs as compared to that in WT BMDMs (Supplementary Fig. 3i ). These results suggest that NOX4-derived mtROS is critical for the regulation of CPT1A protein expression.
Inhibition of FAO suppresses NLRP3 inflammasome activation
To examine whether a genetic deficiency of Cpt1a could suppress caspase-1 activation, we used CRISPR technology and two independent gRNAs to mouse Cpt1a in WT BMDMs. Transduction with Cpt1a-targeting gRNAs resulted in a lower degree of activation of caspase-1, cleavage of IL-1β (Fig. 4a) , and secretion of IL-1β and Fig. 4b) in response to nigericin and ATP treatment as compared to that with the control plasmid, whereas secretion of TNF-α was unchanged (Fig. 4b) . Similarly, the activation of caspase-1, cleavage of IL-1β (Supplementary Fig. 4a) , and secretion of IL-1β and IL-18 ( Supplementary Fig. 4b ) after treatment with nigericin and ATP were lower in response to two independent shRNAs specific for mouse Cpt1a, relative to those for WT peritoneal macrophages expressing a control shRNA, whereas secretion of TNF-α was unchanged (Supplementary Fig. 4b) . Moreover, the production of acetyl-CoA in response to nigericin and ATP treatment was lower after transduction of cells with two independent Cpt1a-specific shRNAs, as compared to that in cells transduced with a control shRNA (Supplementary Fig. 4c) . Consistently, palmitate-BSAinduced activation of caspase-1, cleavage of IL-1β ( Supplementary  Fig. 4d) , and secretion of IL-1β and IL-18 ( Supplementary Fig. 4e ) in response to nigericin and ATP treatment were lower after transduction with a Cpt1a-specific shRNA, whereas secretion of TNF-α was unchanged (Supplementary Fig. 4e ). NLRP3-dependent ASC oligomerization, in response to LPS and nigericin treatment, was lower after transduction with a Cpt1a-targeting gRNA, relative to that for cells transduced with the control plasmid (Fig. 4c) . Furthermore, CPT1A overexpression resulted in higher caspase-1 activation, IL-1β cleavage (Supplementary Fig. 5a ), and IL-1β and IL-18 secretion (Supplementary Fig. 5b ) in response to nigericin in LPS-primed BMDMs than in control plasmid-transduced cells, whereas TNF-α secretion was unchanged (Supplementary Fig. 5b) . The inhibition of caspase-1 activation, IL-1β cleavage (Fig. 4d) and IL-1β and IL-18 secretion (Fig. 4e) was reversed by overexpression of CPT1A in Nox4 −/− BMDMs, as compared to that in control cells, whereas TNF-α secretion was unchanged (Fig. 4e) .
Moreover, as compared to vehicle-treated control cells, treatment of LPS-primed WT BMDMs with etomoxir, a specific inhibitor of CPT1 (ref. 37) , resulted in significantly less secretion of IL-1β and IL-18 in response to nigericin, ATP and (Supplementary Fig. 5c ), whereas secretion of TNF-α was unchanged ( Supplementary  Fig. 5c ). In contrast, the secretion of IL-1β and IL-18 after stimulation , 1 h) or distilled water (control), followed by incubation with PA-BSA, and/or nigericin or ATP after LPS stimulation. TOMM20 and β-actin were used as loading controls for immunoblot analyses. Data are derived from n = 6 (a,b), n = 5 (c), n = 8 (d,e) or n = 6 (f,g) mice. All data are mean ± s.d. **P < 0.01, *P < 0.05; by ANOVA. Data are representative of three independent experiments, and each was done in triplicate. npg with MDP, flagellin or poly(dA:dT) was unchanged by treatment with etomoxir (Supplementary Fig. 5c) . Consistently, the activation of caspase-1 and IL-1β cleavage in response to treatment with nigericin and ATP was lower in response to etomoxir relative to that in vehicle-treated cells (Supplementary Fig. 5d ). Similar to the effects observed after Cpt1a knockdown, etomoxir treatment resulted in lower palmitate-BSA-induced activation of caspase-1, cleavage of IL-1β (Fig. 4f) , and secretion of IL-1β and IL-18 ( Fig. 4g) npg to treatment with nigericin and ATP, as compared to that in vehicle-treated control cells, whereas TNF-α was unchanged (Fig. 4g) . These results suggest that FAO is required for NLRP3 inflammasome activation in response to pro-inflammatory stimuli.
Pharmacological targeting of NLRP3 inflammasome activation
We examined the effects of pharmacologic inhibition of NOX4 on NLRP3 inflammasome activation. Inhibition of NOX4 activity by GKT137831, a potent dual NOX1 and NOX4 inhibitor that is currently in phase 2 clinical trials 38 , resulted in significantly lower secretion of IL-1β and IL-18 in LPS-primed peritoneal macrophages than in vehicle-treated control cells, in response to treatment with nigericin, ATP and silica (Fig. 5a) , whereas secretion of TNF-α was unchanged (Fig. 5a) . GKT137831 treatment lowered IL-1β secretion in a dose-dependent manner in response to nigericin, relative to that in vehicle-treated control cells, whereas TNF-α secretion was unchanged (Fig. 5b) . Moreover, GKT137831 treatment resulted in decreased activation of caspase-1, cleavage of IL-1β (Supplementary Fig. 6a) , and secretion of IL-1β and IL-18 ( Supplementary Fig. 6b ) in LPSprimed WT BMDMs in response to treatment with nigericin and ATP, compared to that in vehicle-treated control cells, whereas secretion of TNF-α was unchanged (Supplementary Fig. 6b ). In contrast, the secretion of IL-1β and IL-18 by MDP or flagellin stimulation was unchanged by GKT137831 (Fig. 5a) . GKT137831 treatment resulted in significantly lower production of mtROS ( Fig. 5c and Supplementary  Fig. 6c) , expression of CPT1A protein (Fig. 5d) , induction of OCR npg by palmitate-BSA ( Fig. 5e and Supplementary Fig. 6d) , and production of FFA and acetyl-CoA ( Fig. 5f and Supplementary  Fig. 6e ) in response to nigericin treatment, relative to that in vehicletreated control cells. Furthermore, GKT137831 treatment resulted in lower palmitate-BSA-induced activation of caspase-1, cleaved IL-1β (Supplementary Fig. 6f ) and secretion of IL-1β and IL-18 ( Fig. 5g) in response to nigericin compared to vehicle control, while TNF-α was unchanged (Fig. 5g) . GKT137831 treatment resulted in significantly lower plasma levels of IL-1β and IL-18 in response to LPS challenge in vivo in WT mice relative to that in vehicle-treated control mice, whereas TNF-α levels were unchanged ( Supplementary  Fig. 6g) . Notably, GKT137831 prophylactically lowered the levels of IL-1β and IL-18 ( Fig. 5h) and the activation of caspase-1 ( Supplementary Fig. 6h ) after S. pneumoniae infection in lung tissues of WT mice, as compared to those in vehicle-treated control mice, whereas TNF-α levels were comparable (Fig. 5h) . These results suggest that GKT137831 treatment reduces NLRP3 inflammasome activation in vitro and in vivo. Because GKT137831 has dual specificity for NOX1 and NOX4 (ref. 38) , we examined the effects of either NOX4 or NOX1 inhibition on NLRP3 inflammasome activation. Treatment with VAS-2870, a specific NOX4 inhibitor 13 , significantly lowered IL-1β secretion in response to nigericin, ATP and silica in LPS-primed WT peritoneal macrophages, as compared to that in vehicle-treated cells (Supplementary Fig. 7a ). In contrast, VAS-2870 treatment had no effect on the secretion of IL-1β in response to MDP, flagellin or poly(dA:dT), as compared to that in vehicle-treated cells (Supplementary Fig. 7a ). VAS-2870 treatment resulted in lower caspase-1 activation, IL-1β cleavage (Supplementary Fig. 7b) , and IL-1β and IL-18 secretion (Supplementary Fig. 7c ) in LPS-primed WT BMDMs in response to nigericin and ATP relative to that in vehicle-treated control cells, whereas TNF-α secretion was unchanged (Supplementary Fig. 7c) . Moreover, VAS-2870 treatment resulted in lower production of mtROS ( Fig. 6a  and Supplementary Fig. 7d) , expression of CPT1A (Fig. 6b) , induction of OCR by palmitate-BSA ( Fig. 6c and Supplementary Fig. 7e) , and levels of FFA and acetyl-CoA ( Fig. 6d and Supplementary  Fig. 7f ) in response to nigericin treatment in LPS-primed WT BMDMs, relative to those in vehicle-treated cells. Consistently, VAS-2870 treatment lowered palmitate-BSA-induced caspase-1 activation, IL-1β cleavage (Supplementary Fig. 7g ) and IL-1β and IL-18 secretion (Fig. 6e) in response to nigericin, as compared to vehicle-treated cells, whereas TNF-α secretion was unchanged (Fig. 6e) .
In contrast, inhibition of NOX1 activity by ML171, a specific NOX1 inhibitor 13 , did not affect activation of caspase-1 ( Supplementary  Fig. 8a ) and secretion of IL-1β, IL-18 and TNF-α in LPS-primed WT peritoneal macrophages in response to nigericin and ATP (Supplementary Fig. 8b,c) , relative to that in control cells. Notably, treatment of LPS-primed primary human macrophages with GKT137831 or VAS-2870 resulted in lower caspase-1 activation, IL-1β cleavage (Fig. 6f,g ) and IL-1β and IL-18 secretion (Fig. 6h) in response to nigericin and ATP exposure, relative to that in vehicle-treated LPS-primed primary human macrophages in response to nigericin and ATP exposure, whereas TNF-α was unchanged (Supplementary Fig. 8d ). Similar to that seen with GKT137831 treatment, VAS-2870 treatment significantly lowered plasma levels of IL-1β and IL-18 in response to LPS challenge in vivo in WT mice, as compared to vehicle-treated control mice, whereas levels of TNF-α were unchanged (Supplementary Fig. 8e) .
Moreover, VAS-2870 treatment prophylactically lowered the levels of IL-1β and IL-18 in WT lung tissues, as compared to those in lung tissue from vehicle-treated control mice, after S. pneumoniae infection (Fig. 6i) ; levels of TNF-α in lung tissue from both groups of mice were comparable (Fig. 6i) . Furthermore, we examined the therapeutic effects of VAS-2870 on the survival of WT mice after S. pneumoniae infection (Supplementary Fig. 8f ). Because the expression of IL-1β is significantly higher at 6 h in S. pneumoniae-infected WT BMDMs than in uninfected BMDMs 18 , we treated WT mice therapeutically with VAS-2870 12 h after S. pneumoniae infection ( Supplementary  Fig. 8f ). VAS-2870 treatment increased the survival of WT mice after S. pneumoniae infection at 150 h post infection, as compared to vehicle-treated control mice (Supplementary Fig. 8f) . In contrast, VAS-2870 treatment did not change the levels of IL-1β, IL-18 and TNF-α after S. pneumoniae infection in lung tissues from Nox4 −/− mice, relative to lung tissues from WT mice ( Supplementary  Fig. 8g ). These results suggest that NOX4 is the pharmacologic target in the pathogenesis of S. pneumoniae.
DISCUSSION
Obesity-induced metabolic diseases, such as insulin resistance or type 2 diabetes, are linked to inflammasome activation 8 . High-fat diet (HFD)-derived fatty acids are important contributors to type 2 diabetes 39, 40 . Recent studies suggest that a HFD or FFAs induce NLRP3 inflammasome activation in adipose tissues and macrophages 4, 8, 41 . Although the role of fatty acids in NLRP3 inflammasome activation has been demonstrated, the molecular targets that trigger oxidation or utilization of fatty acids during NLRP3 inflammasome activation are not well understood. Our findings provide a molecular mechanism by which NOX4-dependent activation of FAO via CPT1A is critical for NLRP3 inflammasome activation by stimuli such as ATP and nigericin. Consistent with our findings, an overload of FFAs, such as palmitate, increases NLRP3 inflammasome activation 4 . Of note, this previous study indicates that inhibition of AMP-activated protein kinase (AMPK) can promote NLRP3 inflammasome activation by LPS and FFAs (such as palmitate), but not by the NLRP3 inflammasome activators used in our study (such as ATP and nigericin 4 ). Consistently, our previous study showed that the function of AMPK is not changed during NLRP3 inflammasome activation by LPS and ATP 6 . Because AMPK is one of the central regulators of cellular energy metabolism 42 , AMPK may modulate FAO and other metabolic pathways that are associated with NLRP3 inflammasome activation, although its role in NOX4-dependent inflammasome regulation remains unclear at present.
Here we demonstrate that NOX4-dependent regulation of FAO promotes the activation of the NLRP3 inflammasome. We also demonstrate that FAO, via CPT1A, is required for NLRP3 inflammasome activation. Furthermore, we show that genetic and pharmacologic inhibition of NOX4 suppresses NLRP3 inflammasome activation in primary human macrophages. Fatty acid metabolism differentially regulates both the priming and activation steps associated with NLRP3 inflammasome regulation in response to pro-inflammatory stimuli 4, 5, 7 . We have previously reported that fatty acid synthesis is required for the priming step in NLRP3 inflammasome regulation 7 .
Here we have demonstrated that NOX4-dependent FAO is required for NLRP3-dependent ASC oligomerization and speck formation during NLRP3 inflammasome activation.
FAO is essential for energy homeostasis and is mainly regulated by mitochondrial FAO via CPT1 (ref. 43 ). The metabolic function of CPT1 is involved in the regulation of insulin secretion by pancreatic beta cells 44, 45 . Similarly, the high levels of FFAs in plasma are linked to insulin resistance 46, 47 . Consistent with these previous studies, npg mitochondrial NOX4 is upregulated in diabetes 16 . Our results indicate that CPT1A-mediated FAO could be a potential pharmacologic target of NOX4 in cellular metabolic pathways. Consistent with previous studies 4, [48] [49] [50] , our results suggest that NOX4-dependent FAO activation might be a metabolic pathway for inflammasome regulation related to the dysfunction of insulin signaling.
Although potential small-molecule inhibitors (such as β-hydroxybutyrate, MCC950) of the NLRP3 inflammasome have been identified 5, 51 , further work will be needed to identify their precise mechanisms of action in advance of their clinical development. Here we describe a mechanism whereby NOX4-dependent CPT1A activation promotes NLRP3 inflammasome activation. Our findings suggest that NOX4 and CPT1A may represent molecular targets for therapeutic inhibitors of the NLRP3 inflammasome. Because our results demonstrate the potential of the NOX1 and NOX4 inhibitor GKT137831, which is currently in phase 2 human clinical trials, as an NLRP3 inflammasome inhibitor, we anticipate the GKT137831 inhibitor to be more appealing for use in inflammatory metabolic human diseases in the future. Furthermore, our results also indicate that NOX4 may represent a pharmacologic target in the treatment of pneumonia.
In conclusion, our current findings demonstrate that the metabolic function of NOX4 could be a therapeutic target in metabolic diseases in which NLRP3-mediated inflammation is implicated in disease pathogenesis.
METHODS
Methods and any associated references are available in the online version of the paper. 
